Bristol-Myers (BMY) to Post Q4 Earnings: What’s in Store?

Bristol-Myers’ (BMY) Q4 earnings might have gained from strong demand for its multiple myeloma drug, Revlimid. Operating expenses might have jumped on costs associated with the broader portfolio.